Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole transdermal - Aequus Pharmaceuticals

Next Previous
Search
Drug Profile

Aripiprazole transdermal - Aequus Pharmaceuticals

Alternative Names: AQS-1301; Transdermal aripiprazole - Aequus

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aequus Pharmaceuticals
  • Developer Aequus Pharmaceuticals; Corium International
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2C receptor partial agonists; Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autistic disorder; Bipolar disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Autistic-disorder(In volunteers) in Canada (Transdermal, Patch)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Bipolar-disorders(In volunteers) in Canada (Transdermal, Patch)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Canada (Transdermal, Patch)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top